COVID-19 Treatment: Eli Lilly Gets DCGI Emergency-Use Approval for Monoclonal Antibody Drugs Bamlanivimab 700 Mg and Etesevimab 1400 Mg
Eli Lilly and Co's antibody drug combination has received an emergency use approval in India. The combination of bamlanivimab 700mg and etesevimab 1,400mg, has been allowed in India for the treatment of patients with mild to moderate COVID-19.
Eli Lilly gets DCGI emergency-use approval for antibody drugs to treat COVID-19
Eli Lilly gets Drugs Controller General of India (DCGI) emergency use approval for its monoclonal antibodies bamlanivimab 700 mg and etesevimab 1400 mg, in India for the treatment of COVID patients with moderate symptoms: Luca Visini, Managing Director, India Subcontinent, Lilly pic.twitter.com/arNU4eZhAc
— ANI (@ANI) June 1, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)
(The above story first appeared on LatestLY on Jun 01, 2021 04:11 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
